Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

OBJECTIVE: Type 2 diabetes is a leading cause of kidney failure, but few outcome trials proactively enrolled individuals with chronic kidney disease (CKD). We performed secondary analyses of cardiovascular (CV) and kidney outcomes across baseline estimated glomerular filtration rate (eGFR) categorie...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Diabetes Care
Main Authors: Perkovic, Vlado, Toto, Robert, Cooper, Mark E., Mann, Johannes F.E., Rosenstock, Julio, McGuire, Darren K., Kahn, Steven E., Marx, Nikolaus, Alexander, John H., Zinman, Bernard, Pfarr, Egon, Schnaidt, Sven, Meinicke, Thomas, von Eynatten, Maximillian, George, Jyothis T., Johansen, Odd Erik, Wanner, Christoph
Formato: Artigo
Idioma:Inglês
Publicado: American Diabetes Association 2020
Assuntos:
Emerging Therapies: Drugs and Regimens
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7372065/
https://ncbi.nlm.nih.gov/pubmed/32444457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc20-0279
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares